Akebia Therapeutics
AKBA
76 hedge funds and large institutions have $58M invested in Akebia Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 10 closing their positions.
484% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $276K
26% more capital invested
Capital invested by funds: $46M → $58M (+$12M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 27.05% → 27% (-0.04%)
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
4% less funds holding
Funds holding: 79 → 76 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.34M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$546K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$479K |
| 4 |
Citigroup
New York
|
+$196K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$404K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$372K |
| 3 |
BlackRock
New York
|
-$364K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$304K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$258K |
AKBA Hedge Fund Activity: Q3 2023 in Review
76 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2023, worth a combined $58M — up 26% from $46M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AKBA and 7 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 19 added.
The largest buyer was Millennium Management, adding an estimated $1.34M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $404K.
- 76 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2023, down from 79 in Q2 2023.
- Funds reported $58M of Akebia Therapeutics stock for Q3 2023, up 26% quarter-over-quarter.
- 7 funds opened new Akebia Therapeutics positions in Q3 2023 and 10 closed out, a net change of -3 holders.
- The largest Akebia Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $1.34M added.
- The largest Akebia Therapeutics seller in Q3 2023 was Qube Research & Technologies (QRT), an estimated $404K sold.
Based on aggregated 13F filings for Q3 2023.